Id |
Subject |
Object |
Predicate |
Lexical cue |
T172 |
0-73 |
Sentence |
denotes |
Name of the player Details of antiviral vaccines under development Ref. |
T173 |
74-248 |
Sentence |
denotes |
Migal Galilee Research Institute, Israel Developing an oral (mucosal) vaccine, wherein the viral antigen is delivered via mucosa tissues by self-activated endocytosis [104] |
T174 |
249-382 |
Sentence |
denotes |
Entos Pharmaceuticals Fusogenix – DNA vaccine is being developed based on its patent protected platform, proteo-lipid vehicle (PLV). |
T175 |
383-464 |
Sentence |
denotes |
It uses a new mechanism for delivering genetic material into the cells [105,106] |
T176 |
465-549 |
Sentence |
denotes |
Vaxart Inc Oral recombinant vaccine in tablet formulation using its VAAST platform. |
T177 |
550-634 |
Sentence |
denotes |
It has protected its vaccine tablet formulation by US patent applications [107–109] |
T178 |
635-765 |
Sentence |
denotes |
University of Oxford – Jenner Institute ChAD0X1 nCoV-19 – prepared from cold virus (weakened) – initiated Phase III trials [110] |
T179 |
766-881 |
Sentence |
denotes |
Altimmune AdCOVID – vaccine delivered via intranasal route platform technologies NasoVAX and NasoShield [111,112] |
T180 |
882-934 |
Sentence |
denotes |
Medicago Developing a vaccine and also an antibody. |
T181 |
935-1002 |
Sentence |
denotes |
It was successful in producing virus like particles of coronavirus. |
T182 |
1003-1076 |
Sentence |
denotes |
It is developing antibodies in collaboration with Laval University [113] |
T183 |
1077-1201 |
Sentence |
denotes |
Inovio Pharmaceuticals INO-4800 – vaccine that is developed in collaboration with Beijing Advaccinee Biotechnology Company. |
T184 |
1202-1357 |
Sentence |
denotes |
It is proposing to deliver the vaccine using the device called as CELLECTRA® which works by creating a pulse for transferring the plasmids across the cell. |
T185 |
1358-1447 |
Sentence |
denotes |
It is also developing INO 4700 in collaboration with GeneOne Life Sciences company [114] |
T186 |
1448-1520 |
Sentence |
denotes |
Moderna mRN 1273 – recently received fast track designation from USFDA. |
T187 |
1521-1586 |
Sentence |
denotes |
It vaccine basically targets spike protein of corona virus [115] |
T188 |
1587-1676 |
Sentence |
denotes |
Tonix Pharmaceuticals TNX-1800 – developed based on its horsepox virus vaccine platform. |
T189 |
1677-1740 |
Sentence |
denotes |
It has filed a provisional patent application with USPTO [116] |
T190 |
1741-1869 |
Sentence |
denotes |
Clover Biopharmaceuticals Subunit vaccine developed using trimeric spike protein developed using its patented technology [117] |
T191 |
1870-2002 |
Sentence |
denotes |
Novavax, Inc Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology. |
T192 |
2003-2137 |
Sentence |
denotes |
The vaccine showed positive results in inhibiting the virus when administered along with its patented adjuvant formulations [118–121] |
T193 |
2138-2338 |
Sentence |
denotes |
Predictive oncology (PO) Introduced artificial intelligence for development of a vaccine using Inventa Biotech’s HSCTM technology which deals with chromatographic system of high throughput screening. |